NCT03972150View on ClinicalTrials.gov

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

October 27, 2020

Study Completion Date

March 28, 2022

Conditions
Neoplasms
Interventions
DRUG

BI 836880

Solution for infusion

DRUG

BI 754091

Solution for infusion

Trial Locations (2)

411-8777

Shizuoka Cancer Center, Shizuoka, Sunto-gun

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03972150 - A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer | Biotech Hunter | Biotech Hunter